Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15711 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Christopher A Gravel und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases, Rhabdomyolysis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
Recent case reports have suggested that sodium‐glucose co‐transporter 2 (SGLT2) inhibitors may interact with statins to increase their risk of myotoxicity. We assessed the risk of myotoxicity reporting associated with concomitant use of SGLT2 inhibitors and statins.
Methods
We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2013 to 2021 for reports including SGLT2 inhibitors, statins or both. We estimated several measures of disproportionate reporting of myopathy and rhabdomyolysis associated with concomitant use of SGLT2 inhibitors and statins: reporting odds ratio (ROR) with 95% confidence interval (CI), Ω shrinkage measure (safety signal if >0) and an extension of the proportional reporting ratio (PRR) (two‐criteria set, safety signal if both criteria are met), using the full FAERS dataset as the reference set. In sensitivity analyses, we focussed on specific SGLT2 inhibitor‐statin pairs with higher interaction potential (canagliflozin‐rosuvastatin, empagliflozin‐rosuvastatin) and accounted for stimulated reporting.
Results
There were 456 myopathy and 77 rhabdomyolysis reports involving both an SGLT2 inhibitor and a statin. Concomitant use of SGLT2 inhibitors and statins was not associated with an increased risk of myopathy (ROR 0.79, 95% CI 0.70 to 0.89) or rhabdomyolysis (ROR 0.58, 95% CI 0.41 to 0.83) reporting. For both outcomes, the Ω shrinkage measure was negative and only one criterion of the PRR extension was met. SGLT2 inhibitor‐statin pairs with higher interaction potential yielded potential signals for rhabdomyolysis; these signals disappeared after accounting for stimulated reporting.
Conclusion
There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2 inhibitors and statins or for specific drug pairs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Risk Sciences International, Ottawa, Ontario, Canada.
- Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
- Department of Medicine, McGill University, Montreal, Quebec, Canada.
- Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
ORCID-Profile: Antonios Douros
Zitieren
APA
Gravel, C. A., Krewski, D., Mattison, D. R., Momoli, F., & Douros, A. (2023). Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15711
Vancouver
Gravel CA, Krewski D, Mattison DR, Momoli F, Douros A. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15711
BibTeX
@article{Gravel2023,
author = {Gravel, Christopher A and Krewski, Daniel and Mattison, Donald R and Momoli, Franco and Douros, Antonios},
title = {Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15711}
}
EUVIMED